Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-blind, placebo-controlled, phase III trial to study the effect of irbesartan on endothelial function of the retinal vasculature in patients with hypercholesterolemia

X
Trial Profile

A randomised, double-blind, placebo-controlled, phase III trial to study the effect of irbesartan on endothelial function of the retinal vasculature in patients with hypercholesterolemia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irbesartan (Primary)
  • Indications Cerebral ischaemia; Hypercholesterolaemia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Nov 2016 Results assessing effect of Valsartan on retinal capillary rarefaction in hypertensive patients (n=150) using patients data from this and other two trials (NCT01318395 and NCT01319344) published in the Journal of Clinical Hypertension (Greenwich)
    • 03 Feb 2010 Actual initiation date (Nov 2009) added as reported by ClinicalTrials.gov
    • 19 Jan 2010 Additional lead trial centre identified as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top